Literature DB >> 24674272

Iron and noncontrast magnetic resonance T2* as a marker of intraplaque iron in human atherosclerosis.

Marshall W Winner1, Travis Sharkey-Toppen1, Xiaolan Zhang1, Michael L Pennell1, Orlando P Simonetti1, Jay L Zweier1, Patrick S Vaccaro1, Subha V Raman2.   

Abstract

OBJECTIVE: Iron has been implicated in atherogenesis and plaque destabilization, whereas less is known about iron-related proteins in this disease. We compared ex vivo quantities with in vivo vessel wall T2*, which is a noncontrast magnetic resonance relaxation time that quantitatively shortens with increased tissue iron content. We also tested the hypothesis that patients with carotid atherosclerosis have abnormal T2* times vs controls that would help support a role for iron in human atherosclerosis.
METHODS: Forty-six patients undergoing carotid endarterectomy and 14 subjects without carotid disease were prospectively enrolled to undergo carotid magnetic resonance imaging. Ex vivo measurements were performed on explanted plaque and 17 mammary artery samples.
RESULTS: Plaques vs normal arteries had higher levels of ferritin (median, 7.3 [interquartile range (IQR), 4-13.8] vs 1.0 [IQR, 0.6-1.3] ng/mg; P < .001) and oxidized low-density lipoprotein (median, 0.17 [IQR, 0.12-0.30] vs 0.01 [IQR, 0.003-0.03] ng/mg; P < .001) as well as hepcidin (median, 8.7 [IQR, 4.6-12.4] vs 2.6 [IQR, 1.3-7.0] ng/mL; P = .03); serum hepcidin levels did not distinguish atherosclerosis patients from controls (median, 40.6 [IQR, 18.8-88.6] vs 33.9 [IQR, 17.6-55.2]; P = .42). Shorter in vivo T2* paralleled larger plaque volume (ρ = -.44; P = .01), and diseased arteries had shorter T2* values compared with controls (median, 17.7 ± 4.3 vs 23.0 ± 2.4 ms; P < .001).
CONCLUSIONS: Diseased arteries have greater levels of iron-related proteins ex vivo and shorter T2* times in vivo. Further studies should help define the role of T2* as a biomarker of iron and atherosclerosis.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24674272      PMCID: PMC4175307          DOI: 10.1016/j.jvs.2014.02.006

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  44 in total

1.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease.

Authors:  John C Wood; J Michael Tyszka; Susan Carson; Marvin D Nelson; Thomas D Coates
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

2.  Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women.

Authors:  Daphne L van der A; Joannes J M Marx; Diederick E Grobbee; Marjolein H Kamphuis; Niki A Georgiou; J Henny van Kats-Renaud; William Breuer; Z Ioav Cabantchik; Mark Roest; Hieronymus A M Voorbij; Yvonne T van der Schouw
Journal:  Circulation       Date:  2006-04-17       Impact factor: 29.690

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Red cells, hemoglobin, heme, iron, and atherogenesis.

Authors:  Emoke Nagy; John W Eaton; Viktória Jeney; Miguel P Soares; Zsuzsa Varga; Zoltán Galajda; József Szentmiklósi; Gábor Méhes; Tamás Csonka; Ann Smith; Gregory M Vercellotti; György Balla; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

5.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

6.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

7.  Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Authors:  John C Wood; Maya Otto-Duessel; Michelle Aguilar; Hanspeter Nick; Marvin D Nelson; Thomas D Coates; Harvey Pollack; Rex Moats
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

8.  Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper.

Authors:  Nadina Stadler; Robyn A Lindner; Michael J Davies
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03-04       Impact factor: 8.311

9.  Iron uptake by ferritin: NMR relaxometry studies at low iron loads.

Authors:  J Vymazal; R A Brooks; J W Bulte; D Gordon; P Aisen
Journal:  J Inorg Biochem       Date:  1998-09       Impact factor: 4.155

10.  Increased ferritin gene expression in atherosclerotic lesions.

Authors:  J H Pang; M J Jiang; Y L Chen; F W Wang; D L Wang; S H Chu; L Y Chau
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more
  5 in total

1.  Iron, inflammation and atherosclerosis risk in men vs. perimenopausal women.

Authors:  Subha V Raman; Travis P Sharkey-Toppen; Tam Tran; Jim X Liu; Beth McCarthy; Xin He; Suzanne Smart; Martha Gulati; Randell Wexler; Orlando P Simonetti; Rebecca D Jackson
Journal:  Atherosclerosis       Date:  2015-03-20       Impact factor: 5.162

2.  Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model.

Authors:  Alain Nchimi; Audrey Courtois; Mounia El Hachemi; Ziad Touat; Pierre Drion; Nadia Withofs; Geoff Warnock; Mohamed-Ali Bahri; Jean-Michel Dogné; Jean-Paul Cheramy-Bien; Laurent Schoysman; Julien Joskin; Jean-Baptiste Michel; Jean-Olivier Defraigne; Alain Plenevaux; Natzi Sakalihasan
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

3.  Transferrin predicts trimethylamine-N-oxide levels and is a potential biomarker of cardiovascular disease.

Authors:  Lamuel D Bean; Jeffrey J Wing; Randall E Harris; Suzanne M Smart; Subha V Raman; M Wesley Milks
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.174

Review 4.  No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biol Rev Camb Philos Soc       Date:  2018-03-25

5.  Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension.

Authors:  Luca Valenti; Alessandro Maloberti; Stefano Signorini; Marta Milano; Francesca Cesana; Fabrizio Cappellini; Paola Dongiovanni; Marianna Porzio; Francesco Soriano; Maura Brambilla; Giancarlo Cesana; Paolo Brambilla; Cristina Giannattasio; Silvia Fargion
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.